LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

AnaptysBio Inc

Închisă

SectorSănătate

22.4 -4.11

Rezumat

Modificarea prețului

24h

Curent

Minim

22.1

Maxim

23.3

Indicatori cheie

By Trading Economics

Venit

-18M

-39M

Vânzări

-15M

28M

EPS

-1.28

Marjă de profit

-141.619

Angajați

136

EBITDA

-24M

-28M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+117.54% upside

Dividende

By Dow Jones

Următoarele câștiguri

1 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

57M

670M

Deschiderea anterioară

26.51

Închiderea anterioară

22.4

Sentimentul știrilor

By Acuity

50%

50%

154 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

AnaptysBio Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 iun. 2025, 23:49 UTC

Câștiguri

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 iun. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 iun. 2025, 21:30 UTC

Câștiguri

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Câștiguri

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 iun. 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 iun. 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 iun. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 iun. 2025, 23:33 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 iun. 2025, 23:30 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 iun. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 iun. 2025, 23:19 UTC

Achiziții, Fuziuni, Preluări

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 iun. 2025, 22:06 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:15 UTC

Câștiguri

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 iun. 2025, 21:07 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 iun. 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 20:52 UTC

Câștiguri

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 iun. 2025, 20:51 UTC

Câștiguri

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

AnaptysBio Inc Așteptări

Obiectiv de preț

By TipRanks

117.54% sus

Prognoză pe 12 luni

Medie 50.86 USD  117.54%

Maxim 90 USD

Minim 25 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAnaptysBio Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

10

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

19.25 / 21.135Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

154 / 380 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.